FDA Panel Recommends Approval of New Antibiotic

From the WebMD Archives

 Nov. 8, 2016 -- A new antibiotic has been narrowly recommended for approval by a U.S. Food and Drug Administration advisory committee.

In voting 7-6 in favor of the drug solithromycin, from North Carolina-based Cempra Inc., the outside panel of experts said the antibiotic's effectiveness outweighs the risks of liver toxicity seen in company studies, the Associated Press reported.

The FDA typically follows the advice of its advisory committees.

Cempra is one of the few drug companies developing new antibiotics amid growing bacterial resistance to older antibiotics, the AP reported.